David Gomez1, Paula Jimenez-Fonseca1, Aránzazu Manzano Fernández2, Patricia Cruz Castellanos3, Maria Valero Arbizu4, Ruth Martínez Cabañes5, David Lorente Estellés6, Estrella Ferreira7, Jorge Del Rio1, Teresa García García8, Alberto Carmona-Bayonas9, Caterina Calderon10. 1. Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, Oviedo, University of País Vasco, País Vasco, Spain. 2. Department of Medical Oncology, Hospital Universitario Clínico San Carlos de Madrid, Madrid, Spain. 3. Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain. 4. Department of Medical Oncology, Hospital Quirónsalud Sagrado Corazón, Sevilla, Spain. 5. Department of Medical Oncology, Hospital Universitario Fundación Alcorcón, Madrid, Spain. 6. Department of Medical Oncology, Hospital Provincial de Castellón, Castellón, Spain. 7. Department of Clinical Psychology and Psychobiology, Faculty of Psychology, University of Barcelona, Barcelona. 8. Department of Medical Oncology, Hospital General Universitario Santa Lucia, Cartagena, Spain. 9. Department of Medical Oncology, Hospital Universitario Morales Meseguer, University of Murcia, IMIB, Murcia, Spain. 10. Department of Clinical Psychology and Psychobiology, Faculty of Psychology, University of Barcelona, Barcelona, University of País Vasco, País Vasco, Spain.
Abstract
BACKGROUND: Despite the causal relationship between obesity and colon cancer being firmly established, the effect of obesity on the course of cancer calls for further elucidation. The objective of this study was to assess differences in clinical-pathological and psychosocial variables between obese and nonobese individuals with colon cancer. MATERIALS AND METHODS: This was a prospective, multicentric, observational study conducted from 2015-2018. The sample comprised patients with stage II-III, resected colon cancer about to initiate adjuvant chemotherapy with fluoropyrimidine in monotherapy or associated with oxaliplatin and grouped into nonobese (body mass index <30 kg/m2 ) or obese (≥30 kg/m2 ). Subjects completed questionnaires appraising quality of life (European Organization for Research and Treatment of Cancer Quality of Life Core questionnaire), coping (Mini-Mental Adjustment to Cancer), psychological distress (Brief Symptom Inventory 18), perceived social support (Multidimensional Scale of Perceived Social Support), personality (Big Five Inventory 10), and pain (Brief Pain Inventory). Toxicity, chemotherapy compliance, 12-month recurrence, and mortality rate data were recorded. RESULTS: Seventy-nine of the 402 individuals recruited (19.7%) were obese. Obese subjects exhibited more comorbidities (≥2 comorbidities, 46.8% vs. 30.3%, p = .001) and expressed feeling slightly more postoperative pain (small size-effect). There was more depression, greater helplessness, less perceived social support from friends, and greater extraversion among the obese versus nonobese subjects (all p < .04). The nonobese group treated with fluoropyrimidine and oxaliplatin suffered more grade 3-4 hematological toxicity (p = .035), whereas the obese had higher rates of treatment withdrawal (17.7% vs. 7.7%, p = .033) and more recurrences (10.1% vs. 3.7%, p = .025). No differences in sociodemographic, quality of life, or 12-month survival variables were detected. CONCLUSION: Obesity appears to affect how people confront cancer, as well as their tolerance to oncological treatment and relapse. IMPLICATIONS FOR PRACTICE: Obesity is a causal factor and affects prognosis in colorectal cancer. Obese patients displayed more comorbidities, more pain after cancer surgery, worse coping, and more depression and perceived less social support than nonobese patients. Severe hematological toxicity was more frequent among nonobese patients, whereas rates of withdrawal from adjuvant chemotherapy were higher in the obese cohort, and during follow-up, obese patients presented greater 12-month recurrence rates. With the growing and maintained increase of obesity and the cancers associated with it, including colorectal cancer, the approach to these more fragile cases that have a worse prognosis must be adapted to improve outcomes.
BACKGROUND: Despite the causal relationship between obesity and colon cancer being firmly established, the effect of obesity on the course of cancer calls for further elucidation. The objective of this study was to assess differences in clinical-pathological and psychosocial variables between obese and nonobese individuals with colon cancer. MATERIALS AND METHODS: This was a prospective, multicentric, observational study conducted from 2015-2018. The sample comprised patients with stage II-III, resected colon cancer about to initiate adjuvant chemotherapy with fluoropyrimidine in monotherapy or associated with oxaliplatin and grouped into nonobese (body mass index <30 kg/m2 ) or obese (≥30 kg/m2 ). Subjects completed questionnaires appraising quality of life (European Organization for Research and Treatment of Cancer Quality of Life Core questionnaire), coping (Mini-Mental Adjustment to Cancer), psychological distress (Brief Symptom Inventory 18), perceived social support (Multidimensional Scale of Perceived Social Support), personality (Big Five Inventory 10), and pain (Brief Pain Inventory). Toxicity, chemotherapy compliance, 12-month recurrence, and mortality rate data were recorded. RESULTS: Seventy-nine of the 402 individuals recruited (19.7%) were obese. Obese subjects exhibited more comorbidities (≥2 comorbidities, 46.8% vs. 30.3%, p = .001) and expressed feeling slightly more postoperative pain (small size-effect). There was more depression, greater helplessness, less perceived social support from friends, and greater extraversion among the obese versus nonobese subjects (all p < .04). The nonobese group treated with fluoropyrimidine and oxaliplatin suffered more grade 3-4 hematological toxicity (p = .035), whereas the obese had higher rates of treatment withdrawal (17.7% vs. 7.7%, p = .033) and more recurrences (10.1% vs. 3.7%, p = .025). No differences in sociodemographic, quality of life, or 12-month survival variables were detected. CONCLUSION:Obesity appears to affect how people confront cancer, as well as their tolerance to oncological treatment and relapse. IMPLICATIONS FOR PRACTICE: Obesity is a causal factor and affects prognosis in colorectal cancer. Obesepatients displayed more comorbidities, more pain after cancer surgery, worse coping, and more depression and perceived less social support than nonobese patients. Severe hematological toxicity was more frequent among nonobese patients, whereas rates of withdrawal from adjuvant chemotherapy were higher in the obese cohort, and during follow-up, obesepatients presented greater 12-month recurrence rates. With the growing and maintained increase of obesity and the cancers associated with it, including colorectal cancer, the approach to these more fragile cases that have a worse prognosis must be adapted to improve outcomes.
Authors: Caterina Calderón; Pere J Ferrando; Urbano Lorenzo-Seva; David Gómez-Sánchez; Ana Fernández-Montes; Maria Palacín-Lois; Mónica Antoñanzas-Basa; Jacobo Rogado; Aránzazu Manzano-Fernández; Estrella Ferreira; Elena Asensio-Martínez; Paula Jiménez-Fonseca Journal: Psicothema Date: 2021-02
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: J Clin Epidemiol Date: 2008-04 Impact factor: 6.437
Authors: Cherise B Harrington; Jennifer A Hansen; Michal Moskowitz; Briana L Todd; Michael Feuerstein Journal: Int J Psychiatry Med Date: 2010 Impact factor: 1.210
Authors: Floriana S Luppino; Leonore M de Wit; Paul F Bouvy; Theo Stijnen; Pim Cuijpers; Brenda W J H Penninx; Frans G Zitman Journal: Arch Gen Psychiatry Date: 2010-03
Authors: James J Dignam; Blase N Polite; Greg Yothers; Peter Raich; Linda Colangelo; Michael J O'Connell; Norman Wolmark Journal: J Natl Cancer Inst Date: 2006-11-15 Impact factor: 13.506
Authors: Maciej Majchrzak; Anna Brzecka; Cyryl Daroszewski; Piotr Błasiak; Adam Rzechonek; Vadim V Tarasov; Vladimir N Chubarev; Anastasiya S Kurinnaya; Tatiana I Melnikova; Alfiya Makhmutova; Sergey G Klochkov; Siva G Somasundaram; Cecil E Kirkland; Gjumrakch Aliev Journal: Front Pharmacol Date: 2019-06-14 Impact factor: 5.810